PL363431A1 - The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders - Google Patents
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disordersInfo
- Publication number
- PL363431A1 PL363431A1 PL01363431A PL36343101A PL363431A1 PL 363431 A1 PL363431 A1 PL 363431A1 PL 01363431 A PL01363431 A PL 01363431A PL 36343101 A PL36343101 A PL 36343101A PL 363431 A1 PL363431 A1 PL 363431A1
- Authority
- PL
- Poland
- Prior art keywords
- copolymer
- treatment
- nervous system
- central nervous
- system disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58752300A | 2000-06-05 | 2000-06-05 | |
PCT/US2001/018248 WO2001093828A1 (en) | 2000-06-05 | 2001-06-05 | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PL363431A1 true PL363431A1 (en) | 2004-11-15 |
Family
ID=24350145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL01363431A PL363431A1 (en) | 2000-06-05 | 2001-06-05 | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1292279A4 (hu) |
JP (1) | JP2003535118A (hu) |
AU (2) | AU7528001A (hu) |
CA (1) | CA2411536A1 (hu) |
HU (1) | HUP0302333A3 (hu) |
IL (1) | IL153236A0 (hu) |
PL (1) | PL363431A1 (hu) |
WO (1) | WO2001093828A1 (hu) |
ZA (1) | ZA200210084B (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
WO2003048735A2 (en) | 2001-12-04 | 2003-06-12 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
CZ30474U1 (cs) | 2009-08-20 | 2017-03-14 | Yeda Research And Development Co., Ltd. | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
EP3185882B1 (en) | 2014-08-29 | 2019-10-09 | Aarhus Universitet | Positively charged co-polymers for use as antimicrobial agents |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CN106924175B (zh) * | 2015-12-29 | 2020-07-03 | 深圳翰宇药业股份有限公司 | 一种治疗多发性硬化症的药物组合物 |
JP2019519515A (ja) | 2016-05-20 | 2019-07-11 | シーダーズ—シナイ メディカル センター | アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法 |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
GB9411292D0 (en) * | 1994-06-06 | 1994-07-27 | Teva Pharma | Pharmaceuticals compositions |
US5665764A (en) * | 1995-06-02 | 1997-09-09 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
US20020037848A1 (en) * | 2000-06-07 | 2002-03-28 | Michal Eisenbach-Schwartz | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
-
2001
- 2001-06-05 HU HU0302333A patent/HUP0302333A3/hu unknown
- 2001-06-05 JP JP2002501401A patent/JP2003535118A/ja active Pending
- 2001-06-05 IL IL15323601A patent/IL153236A0/xx unknown
- 2001-06-05 WO PCT/US2001/018248 patent/WO2001093828A1/en not_active Application Discontinuation
- 2001-06-05 PL PL01363431A patent/PL363431A1/xx not_active Application Discontinuation
- 2001-06-05 EP EP01941973A patent/EP1292279A4/en not_active Withdrawn
- 2001-06-05 AU AU7528001A patent/AU7528001A/xx active Pending
- 2001-06-05 AU AU2001275280A patent/AU2001275280B2/en not_active Ceased
- 2001-06-05 CA CA002411536A patent/CA2411536A1/en not_active Abandoned
-
2002
- 2002-12-12 ZA ZA200210084A patent/ZA200210084B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7528001A (en) | 2001-12-17 |
WO2001093828A1 (en) | 2001-12-13 |
EP1292279A4 (en) | 2005-01-12 |
CA2411536A1 (en) | 2001-12-13 |
EP1292279A1 (en) | 2003-03-19 |
HUP0302333A2 (hu) | 2003-11-28 |
HUP0302333A3 (en) | 2005-07-28 |
AU2001275280B2 (en) | 2006-03-16 |
IL153236A0 (en) | 2003-07-06 |
JP2003535118A (ja) | 2003-11-25 |
ZA200210084B (en) | 2003-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153236A0 (en) | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders | |
HUP0100069A3 (en) | 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders | |
HUP0004439A3 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
HK1046274A1 (en) | Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders. | |
AU9112201A (en) | Pulmonary delivery in treating disorders of the central nervous system | |
HUP0100786A3 (en) | Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them | |
IL151946A0 (en) | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders | |
HUP0401023A3 (en) | Use of flibanserin in the treatment of sexual disorders | |
MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
EP0924983A4 (en) | S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS | |
AU2001266152A1 (en) | Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them | |
IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
ZA97741B (en) | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders. | |
AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
HUP0204050A3 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone | |
IL160018A0 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
EP1079764A4 (en) | TREATMENT OF SEXUALITY DISORDERS IN CERTAIN GROUPS OF PATIENTS | |
GB0015228D0 (en) | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders | |
HUP0301553A3 (en) | Pharmaceutical compositions and their use for treating neurological disorders | |
AU2002226060A1 (en) | Compositions containing gangliosides for use in the treatment of skin disorders | |
IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
AU5963396A (en) | Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders | |
AU2002210763A1 (en) | Use of 1-ebio in the treatment of bipolar disorders | |
AU6330300A (en) | Use of interleukin-6 in treatment of obesity and/or obesity associated disorders | |
AU2001292500A1 (en) | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |